These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

614 related items for PubMed ID: 19664404

  • 1. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
    Danchin N.
    Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
    [Abstract] [Full Text] [Related]

  • 2. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 3. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J, Varela A.
    Am J Cardiovasc Drugs; 2009 Nov; 9 Suppl 1():9-12. PubMed ID: 20000882
    [Abstract] [Full Text] [Related]

  • 4. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
    Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators.
    Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
    [Abstract] [Full Text] [Related]

  • 5. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
    Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I, Steg PG, Fox K, BEAUTIFUL Investigators.
    Am J Cardiol; 2011 Mar 15; 107(6):805-11. PubMed ID: 21247517
    [Abstract] [Full Text] [Related]

  • 6. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 7. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 8. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
    Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators.
    Lancet; 2008 Sep 06; 372(9641):807-16. PubMed ID: 18757088
    [Abstract] [Full Text] [Related]

  • 9. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul 06; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 10. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K.
    Eur Heart J; 2013 Aug 06; 34(29):2263-70. PubMed ID: 23536611
    [Abstract] [Full Text] [Related]

  • 11. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 06; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 12. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D, Goode KM, Cleland JG, Clark AL.
    Heart; 2011 Dec 06; 97(23):1961-6. PubMed ID: 21917660
    [Abstract] [Full Text] [Related]

  • 13. Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine.
    Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ.
    Transplantation; 2007 Oct 27; 84(8):988-96. PubMed ID: 17989604
    [Abstract] [Full Text] [Related]

  • 14. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
    López-Bescós L, Filipova S, Martos R.
    Cardiology; 2007 Oct 27; 108(4):387-96. PubMed ID: 17890862
    [Abstract] [Full Text] [Related]

  • 15. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Oct 27; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 16. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
    Ferrari R, Ceconi C.
    Expert Rev Cardiovasc Ther; 2011 Aug 27; 9(8):959-73. PubMed ID: 21878041
    [Abstract] [Full Text] [Related]

  • 17. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Aug 27; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 18. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
    Filipovský J.
    Vnitr Lek; 2009 May 27; 55(5):513-6. PubMed ID: 19514618
    [Abstract] [Full Text] [Related]

  • 19. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan 27; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction.
    Sette A, Martino A, Lioy E, Calò L.
    J Cardiovasc Electrophysiol; 2010 Jul 27; 21(7):815-7. PubMed ID: 20233274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.